Trial Outcomes & Findings for Investigation of TEST (Transcranial Electric Stimulation Therapy) for Chronic Pain (NCT NCT05113563)
NCT ID: NCT05113563
Last Updated: 2025-04-01
Results Overview
Feasibility will be assessed by the percent of participants start study procedures and complete these
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
6 participants
Primary outcome timeframe
4 weeks
Results posted on
2025-04-01
Participant Flow
Participant milestones
| Measure |
Active Group
All participants received open label TEST
|
|---|---|
|
Overall Study
STARTED
|
6
|
|
Overall Study
COMPLETED
|
6
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Investigation of TEST (Transcranial Electric Stimulation Therapy) for Chronic Pain
Baseline characteristics by cohort
| Measure |
Active Group
n=6 Participants
All participants received open label TEST
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
6 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
|
Age, Continuous
|
39 years
STANDARD_DEVIATION 14 • n=5 Participants
|
|
Sex: Female, Male
Female
|
5 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
4 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
2 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
2 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
2 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
6 participants
n=5 Participants
|
|
Number enrolled in study who completed
|
6 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 4 weeksPopulation: all participants entered to study procedures
Feasibility will be assessed by the percent of participants start study procedures and complete these
Outcome measures
| Measure |
Active Group
n=6 Participants
All participants received open label TEST
|
|---|---|
|
Feasibility Will be Assessed by the Percent of Participants Who Complete
|
6 Participants
|
Adverse Events
Active Group
Serious events: 1 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Active Group
n=6 participants at risk
All participants received open label TEST
|
|---|---|
|
Musculoskeletal and connective tissue disorders
participant experienced symptoms from stopping medication (not a study procedure)
|
16.7%
1/6 • Number of events 1 • 1 month
Definition was not different from clinical trials.gov
|
|
Psychiatric disorders
participant experienced fatigue and depressed mood after taking medication (not a study procedure)
|
16.7%
1/6 • Number of events 1 • 1 month
Definition was not different from clinical trials.gov
|
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place